In the long human struggle against cancer's most stubborn forms, a small injection has offered something rare — genuine surprise. Researchers in London have reported that amivantamab, a bispecific antibody already approved for certain lung cancers, shrank tumors in nearly half of patients whose head and neck cancers had resisted every standard treatment, with fifteen individuals achieving complete remission. Presented to the American Society of Clinical Oncology, the findings arrive as a quiet but significant turning point for a population that had, in the most practical sense, run out of road
thestar.com.my
· May 31, 2026
· health
· 3 min de leitura
High
Apuração: Verificado
Cancer injection eradicates tumours in treatment-resistant cases
Patients with treatment-resistant head and neck cancer experienced significant quality-of-life improvements, including reduced pain, swelling, and elimination of severe chemotherapy side effects.
◉
Health & Medicine
8293 artigos relacionados
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% correspondência
Shingles Vaccine Linked to 24% Lower Dementia Risk in Major Study
Google News · 99% correspondência
DRC Ebola Outbreak Poses Unique Challenges: Limited Treatments, Remote…
Newswise · 99% correspondência
Shingles Vaccine Linked to Lower Dementia Risk in Older Adults
Google News · 99% correspondência
Israel treats suspected first Ebola case as DRC outbreak spreads
The Times of Israel · 99% correspondência
Cobertura Relacionada
7NEWS · Aug 23
Model's Foot Cut Led to Heart Surgery, Baby Loss—Now Advocating for Better Diagnostics
Australian model Leah Ramsey lost her baby after a small foot cut triggered a rare heart infection that was repeatedly m…
Informanté · Aug 23 South Africa Shares FMD Vaccines as Region Strengthens Disease ControlsSouth Africa reports its largest-ever FMD outbreak is coming under control through accelerated vaccination and regional …
Al Jazeera · Aug 23 Solar telemedicine kiosks expand healthcare access across rural ChadSolar-powered telemedicine kiosks in rural Chad enable remote doctor consultations at a fraction of traditional travel c…
Inquirer.net · Aug 23 Prince Harry returns to UK amid family rifts, seeking reconciliation with monarchyPrince Harry and Meghan Markle are relocating back to Britain after six years in California, potentially signaling recon…
Viés e Enquadramento
⚖
Article presents promising cancer treatment results with optimistic framing and expert endorsement, but lacks critical perspective on limitations, side effects, and commercial interests.
Bias Direction
center-right
Confidence
MED
Positive medical breakthrough narrative emphasizing clinical success and patient testimonials, with prominent expert validation and minimal counterbalance on uncertainties or commercial context.
unprecedentedly strong responses
eradicated entire tumours
very striking
potential to benefit many thousands
life-impacting side effects
extremely limited
Cost and accessibility concerns for patients in different healthcare systems
Long-term follow-up data and durability of responses
Comparison with competing treatments in development
Potential adverse effects beyond chemotherapy comparison
Independent analysis not affiliated with trial sponsors
Patient advocacy group perspectives on realistic expectations
Regulatory pathway and timeline to market availability
Johnson & Johnson's commercial interests and pricing strategy
Impacto Geopolítico
🌎
New injectable cancer treatment shows breakthrough efficacy in treatment-resistant cases, with potential global health implications and pharmaceutical market shifts favoring advanced biotechnology.
Escalation Risk
low
Confidence
HIGH
United Kingdom
United States
European Union
Global healthcare systems
11 countries participating in trial
Johnson & Johnson strengthens market position in oncology; UK/EU research institutions gain prestige; potential shift in cancer treatment paradigm from chemotherapy-dependent to targeted immunotherapy approaches; developing nations may face access/affordability challenges for advanced treatments.
Similar to the introduction of monoclonal antibodies (Herceptin, 1998) which revolutionized cancer treatment and reshaped pharmaceutical competition, establishing new standards of care and market dominance.
Lente Econômica
📈
Amivantamab injection shows strong efficacy in treatment-resistant head and neck cancer, potentially expanding addressable market for oncology therapeutics and creating new revenue streams for Johnson & Johnson.
Market Signal
bullish
Confidence
HIGH
Pharmaceutical and Biotechnology
Healthcare Services and Hospitals
Medical Devices and Diagnostics
Health Insurance
Patients gain access to effective treatment option with fewer side effects and easier administration (injection vs. intravenous drips), potentially reducing healthcare burden and improving quality of life for treatment-resistant cancer patients and their families.
Regulatory bodies (FDA, EMA) may accelerate approval pathways; healthcare systems must evaluate reimbursement and budget allocation for new oncology treatments; potential for expanded clinical trial requirements; pricing negotiations between governments and pharmaceutical companies likely to intensify.